In vitro evaluation of the immune-skewing potential of different candidate building blocks for nanoparticle-based allergen immunotherapy for treatment of allergy*

Recruiting

• Conditions: Allergy; Hypersensitivity; 10001708

• Registration Number: NL-OMON54501
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

-Subjects with doctor-diagnosed allergic rhinitis or convincing history of
HDM-allergic rhinitis and a positive SPT and/or serum IgE levels for HDM, cat
or pollen allergens
-Subjects with doctor-diagnosed non-allergic rhinitis or a convincing history
of non-allergic rhinitis and a negative SPT and/or no serum IgE levels for HDM,
cat or pollen allergens
-Subjects with a convincing history of peanut allergy and positive SPT and/or
serum IgE levels for peanut allergens
-Healthy subjects, defined as not having allergic or non-allergic rhinitis or
other inflammatory non-communicable diseases such as rheumatoid arthritis, type
2 diabetes, celiac disease, colitis ulcerosa, Chrohn*s disease, and multiple
sclerosis.

-Aged between 18-65
- signed informed consent

Exclusion Criteria

• History of AIT (SCIT or SLIT) with any allergen within the past year of the
time of blood donation.
• Ongoing AIT (SCIT or SLIT) with any allergen at the time of blood donation.
• Vaccination within one week before blood donation.
• Immunosuppressive or biological medication (e.g. IL-5, anti-IgE therapy)
within the last six months prior to blood donation.
• Severe immune disorders (including auto-immune diseases) and/or diseases
requiring immunosuppressive drugs.
• Active malignancies or any malignant disease during the previous 5 years.
• Active inflammation or infection at the time of blood donation.
• Use of systemic steroids within 4 weeks before the blood donation.
• Treatment with systemic and local β-blockers.
• Volunteers who are students or employees ofone of the participating research
groups or 1st grade relatives or partners of the investigators

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>